Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy

Urology

Volumn 62, Issue 3, 2003, Pages 476-480

  Köllermann, Jens ^a   Caprano, Jörg ^b   Budde, Anke ^b   Weidenfeld, Helga ^b   Weidenfeld, Michael ^b   Hopfenmüller, Werner ^b   Helpap, Burkhard ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; RELAPSE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY TRACT;

EID: 0041733417     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00351-0     Document Type: Article

References (22)

1. Fair W.R., Cookson M.S., Stroumbakis N., et al. Update on neoadjuvant androgen deprivation therapy and radical prostatectomy in localized prostate cancer. J Urol. 155:(suppl):1996;667A.
2. Pedersen K.V., Lundberg S., Hugosson J., et al. Neoadjuvant hormonal treatment with triptorelin versus no treatment prior to radical prostatectomy a prospective, randomized, multicenter study . J Urol. 153:(suppl):1995;391A.
3. Soloway M.S., Sharifi R., Wajsman Z., et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol. 154:1995;424-428.
4. Labrie F., Cusan L., Gomez J.L., et al. Downstaging of early stage prostate cancer before radical prostatectomy the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone releasing hormone agonist . Urology. 4:1994;29-33.
5. Klotz L.H., Goldenberg L.S., Bullock M.J., et al. Neoadjuvant cyproterone acetate therapy prior to radical prostatectomy reduced tumor burden and margin positivity without altering 6 and 12 months post treatment PSA results of a randomized trial . J Urol. 155:(suppl):1996;399A.
6. Bellavance G., Fradet Y. Influence of neoadjuvant hormone therapy on PSA response and pathological stage at radical prostatectomy. J Urol. 155:(suppl):1996;651A.
7. Debruyne F.M.J., Forster G., Schulman C.C., et al. European study of neoadjuvant combined androgen deprivation therapy in T2-3 prostatic carcinoma. J Urol. 155:(suppl):1996;645A.
8. Van Poppel H., De Ridder D., Elgamal A.A., et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer interim results of a prospective randomized trial . J Urol. 154:1995;429-434.
9. Bono A.V., Pagano F., Montironi R., et al. Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer progress pathology report of the Italian PROSIT study . Urology. 57:2001;117-121.
10. Ramos C.G., Carvalhal G.F., Smith D.S., et al. Clinical and pathological characteristics and recurrence rates of stage T1c vs. T2a or T2b prostate cancer. J Urol. 161:1999;1525-1529.
11. Han M., Partin A.W., Pound C.R., et al. Long term biochemical disease free and cancer specific survival following anatomic radical retropubic prostatectomy. Urol Clin North Am. 28:2001;555-565.
12. Fair W.R., Betancourt J.E. Update on Memorial Sloan Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Mol Urol. 4:2000;241-248.
13. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol. 167:2002;528-534.
14. Schulman C.C., Debruyne F.M.J., Forster G., et al. 4 year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol. 38:2000;706-713.
15. Cookson M.S., Sogani P.C., Russo P., et al. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer results of a phase II study . Br J Urol. 79:1997;432-438.
16. Van der Kwast T.H., Tetu B., Candas B., et al. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume three versus six months of endocrine therapy . Urology. 53:1999;523-529.
17. Gleave M.E., La Bianca S.E., Goldenberg S.L., et al. Long term neoadjuvant hormone therapy prior to radical prostatectomy evaluation of risk for biochemical recurrence at 5 year follow-up . Urology. 56:2000;289-294.
18. Meyer F., Bairati I., Bedard C., et al. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease free survival in men with prostate cancer. Urology. 58:(suppl 2A):2001;71-77.
19. Köllermann M.W., Pantel K., Enzmann T.H., et al. Supersensitive PSA monitored neoadjuvant hormone treatment of clinically localized prostate cancer effects on positive margins, tumor detection and epithelial cells in bone marrow . Eur Urol. 34:1998;318-324.
20. Köllermann J., Feek U., Müller H., et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol. 38:2000;714-720.
21. Schmid H.P., McNeal J.E., Stamey T.A. Clinical observations on the doubling time of prostate cancer. Eur Urol. 23:1993;60-63.
22. Gleave M.E., Goldenberg S.L., Jones E.C., et al. Biochemical and pathologic effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol. 155:1996;213-219.